Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of “Buy” by Analysts

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) have been given a consensus rating of “Buy” by the eight research firms that are covering the firm, MarketBeat reports. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $21.57.

Several analysts recently weighed in on ZVRA shares. JMP Securities began coverage on shares of Zevra Therapeutics in a research note on Tuesday, September 24th. They issued an “outperform” rating and a $17.00 price objective on the stock. Canaccord Genuity Group decreased their price target on Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a research note on Thursday, November 14th. Cantor Fitzgerald began coverage on Zevra Therapeutics in a research note on Wednesday, January 8th. They issued an “overweight” rating and a $25.00 price objective on the stock. Guggenheim initiated coverage on shares of Zevra Therapeutics in a research report on Monday, October 7th. They set a “buy” rating and a $20.00 target price for the company. Finally, Maxim Group boosted their price target on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a research report on Tuesday, September 24th.

Zevra Therapeutics Trading Up 1.5 %

Shares of Zevra Therapeutics stock opened at $8.05 on Tuesday. The firm has a market capitalization of $429.71 million, a PE ratio of -4.09 and a beta of 2.01. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.84. The firm’s 50 day moving average is $8.68 and its 200 day moving average is $7.80. Zevra Therapeutics has a 1 year low of $4.20 and a 1 year high of $9.76.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its earnings results on Tuesday, November 12th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.25). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The firm had revenue of $3.70 million during the quarter, compared to analyst estimates of $5.04 million. During the same period in the previous year, the company earned ($0.40) EPS. Equities research analysts forecast that Zevra Therapeutics will post -1.95 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Rhumbline Advisers lifted its holdings in shares of Zevra Therapeutics by 17.9% in the 2nd quarter. Rhumbline Advisers now owns 56,874 shares of the company’s stock worth $279,000 after purchasing an additional 8,619 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Zevra Therapeutics by 15.2% during the second quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock valued at $91,000 after buying an additional 2,452 shares during the last quarter. Sanctuary Advisors LLC bought a new stake in shares of Zevra Therapeutics during the second quarter worth about $474,000. SG Americas Securities LLC acquired a new stake in shares of Zevra Therapeutics in the 3rd quarter worth about $105,000. Finally, City State Bank lifted its position in Zevra Therapeutics by 14.1% in the 3rd quarter. City State Bank now owns 16,224 shares of the company’s stock valued at $113,000 after acquiring an additional 2,000 shares in the last quarter. 35.03% of the stock is owned by institutional investors and hedge funds.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.